Wilmington Savings Fund Society’s CRISPR Therapeutics CRSP Stock Holding History

Wilmington Savings Fund Society’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$19.1K	Hold	350	–	–	﹤0.01%	1096
2026 Q1	$16.6K	Hold	350	–	–	﹤0.01%	1118
2025 Q4	$18.4K	Hold	350	–	–	﹤0.01%	1097
2025 Q3	$22.7K	Hold	350	–	–	﹤0.01%	1048
2025 Q2	$17K	Sell	350 -1,000	-74%	-$38.7K	﹤0.01%	1512
2025 Q1	$45.9K	Buy	1,350 +500	+59%	+$21.2K	﹤0.01%	1227
2024 Q4	$33.5K	Hold	850	–	–	﹤0.01%	1349
2024 Q3	$39.9K	Buy	+850	New	+$43.1K	﹤0.01%	1272

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Wilmington Savings Fund Society's CRSP Position: Q2 2026 in Review

Wilmington Savings Fund Society held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 350 shares worth $19.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1096.

Wilmington Savings Fund Society first reported a position in CRSP in Q3 2024 and has held it in 8 quarters since. The position peaked at $45.9K in Q1 2025. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

Wilmington Savings Fund Society held 350 shares of CRISPR Therapeutics worth $19.1K as of Q2 2026.
Wilmington Savings Fund Society left its CRISPR Therapeutics share count unchanged in Q2 2026.
CRISPR Therapeutics made up ﹤0.01% of Wilmington Savings Fund Society's portfolio in Q2 2026, its #1096 holding.
Wilmington Savings Fund Society first reported a position in CRISPR Therapeutics in Q3 2024 and has held it in 8 quarters since.
Wilmington Savings Fund Society's CRISPR Therapeutics position peaked at $45.9K in Q1 2025.
521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Wilmington Savings Fund Society's 13F filing for Q2 2026, filed 28 Jul 2026.